This Week’s IPOs: Biotechs and a Cloud Play

The companies develop biofuel feedstocks, cancer treatments, and a cloud-based video-management platform

   

Last week we had 10 IPOs, with an average return of 16%. Caesars (NASDAQ:CZR) was a big contributor — it soared 58.20%. But there were six other deals that saw double-digit returns as well:

company ticker return (%)
Homestreet HMST 0.00
GSE GSE 27.80
Synacor SYNC 5.00
FX Alliance FX 11.10
Caesars CZR 58.20
Cementos Pacasmayo CPAC -4.30
ChemoCentryx CCXI 11.30
EPAM Systems EPAM 16.30
Roundys RNDY 20.20
Cempra CEMP 14.56

This week there are only three IPOs planned. Let’s take a look at each:

Ceres (NASDAQ:CERE). The company sells seeds to produce renewable bioenergy feedstocks, which helps reduce reliance on petroleum fuels.

But Ceres’ products are still in the early stages, and sales were only $6.6 million last year, with a net loss of $36.3 million.

The lead underwriter on the deal is Goldman Sachs (NYSE:GS). Ceres plans to issue 5 million shares at a price range of $16 to $17 each, which is down from the prior range of $21 to $23 (indicating soft demand for the transaction).

Brightcove (NASDAQ:BCOV). The company develops a cloud-based platform that allows companies to distribute and manage videos as well as mobile apps.

From 2008 to 2011, revenues jumped from $24.5 million to $63.6 million. But there was a loss of $17.3 million last year.

The company plans to sell 5 million shares at a price range of $10 to $12. The lead underwriter is Morgan Stanley (NYSE:MS).

TVAX Biomedical (NASDAQ:TVAX). This biotech focuses on the development of targeted cell-based treatments for cancer. This involves the use of a cancer cell vaccination and the activation of killer T cells.

After the public offering, the company plans to run a Phase III clinical trial.

TVAX plans to sell 2 million shares at a range of $9 to $11. The lead underwriter is Roth Capital.

Tom Taulli runs the InvestorPlace blog IPO Playbook, a site dedicated to the hottest news and rumors about initial public offerings. He also is the author of “The Complete M&A Handbook”“All About Short Selling” and “All About Commodities.” Follow him on Twitter at @ttaulli or reach him via email. As of this writing, he did not own a position in any of the aforementioned securities.


Article printed from InvestorPlace Media, http://investorplace.com/ipo-playbook/this-weeks-ipos-biotechs-and-a-cloud-play/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.